STOCK TITAN
  1. Home
  2. Sec-filings
  3. TXG
  4. [Form 4] 10x Genomics, Inc. Insider Trading Activity

10x Genomics, Inc. reported $642.8M in revenue and a $43.5M net loss for fiscal 2025. See the full TXG financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

10x Genomics CEO sells 13,261 TXG shares to cover taxes

10x Genomics, Inc. (TXG) Chief Executive Officer and Director Serge Saxonov reported a sale of Class A common stock in a Form 4 filing.

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) Chief Executive Officer and Director Serge Saxonov reported a sale of Class A common stock in a Form 4 filing. On 11/24/2025, he sold 13,261 shares at an average price of $18.9983 per share in a transaction coded "S," which the notes explain was to cover tax withholding obligations from vesting restricted stock units.

After this transaction, Saxonov beneficially owns 1,021,556 Class A shares directly. He also reports indirect ownership of 27 shares through the Andromeda Trust, 213,250 shares through the Y/S Descendants' Trust, and 58,000 shares through the Y/S Pot Trust, where he serves as trustee.

Positive

  • None.

Negative

  • None.
Insider Saxonov Serge
Role Chief Executive Officer
Sold 13,261 shs ($252K)
Type Security Shares Price Value
Sale Class A Common Stock 13,261 $18.9983 $252K
holding Class A Common Stock -- -- --
holding Class A Common Stock -- -- --
holding Class A Common Stock -- -- --
Holdings After Transaction: Class A Common Stock — 1,021,556 shares (Direct); Class A Common Stock — 271,277 shares (Indirect, See footnote)
Footnotes (4)
  1. F1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
  2. F2. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
  3. F3. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
  4. F4. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

FAQ

What did 10x Genomics (TXG) disclose in this Form 4 filing?

The filing reports that Chief Executive Officer and Director Serge Saxonov sold 13,261 shares of 10x Genomics Class A common stock on 11/24/2025 in a transaction coded "S."

Why did the TXG insider sell 13,261 shares of Class A common stock?

The explanation states that the 13,261 shares were sold to cover tax withholding obligations related to the vesting of restricted stock units.

What price did Serge Saxonov receive for the TXG shares sold?

The 13,261 shares of 10x Genomics Class A common stock were sold at an average price of $18.9983 per share.

How many TXG shares does Serge Saxonov own after this transaction?

Following the reported sale, Serge Saxonov directly owns 1,021,556 shares of 10x Genomics Class A common stock.

What indirect TXG shareholdings are reported for Serge Saxonov?

He reports indirect ownership of 27 shares held by the Andromeda Trust, 213,250 shares held by the Y/S Descendants' Trust, and 58,000 shares held by the Y/S Pot Trust, each with Saxonov serving as trustee.

What is Serge Saxonov’s role at 10x Genomics (TXG)?

The filing identifies Serge Saxonov as both a Director and an Officer, serving as the company’s Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Saxonov Serge
(Last) (First) (Middle)
10X GENOMICS, INC.
6230 STONERIDGE MALL ROAD
(Street)
PLEASANTON CA 94588
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 11/24/2025 S(1) 13,261 D $18.9983 1,021,556 D
Class A Common Stock 27 I See footnote(2)
Class A Common Stock 213,250 I See footnote(3)
Class A Common Stock 58,000 I See footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
2. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
3. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
4. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
/s/ Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov 11/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR